osimertinib
astrazeneca
[]
 standing ovation, for sure! if they report anything about osi after progression in control arm at asco, they will probably pool together all data for secondary lines of therapy received and will not report how briskly osi was initiated after progression. for example, even if osi 
Medical physicist➡️MD. Passionate about everything #radonc. Focus on QoL, LR-PFS 🎯, constraints🙅‍♀️, isotoxicity ⚖️ and OS. #RadOncCalc @RadOncReview